Actively Recruiting
Sprayed-In Medicated Powder for Less-Invasive Epistaxis Treatment Using Tranexamic Acid The Bloody SIMPLE Treatment Pilot Study
Led by Dr. Anne Conlin · Updated on 2025-05-30
24
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
D
Dr. Anne Conlin
Lead Sponsor
U
University of Ottawa
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating a new treatment method for nosebleeds, which are common and sometimes require emergency care. Typically, nosebleeds are stopped by burning the nose or inserting nasal packing, both of which can cause pain and carry risks, including rare but serious complications. This study is investigating whether tranexamic acid powder sprayed directly into the nose can be an effective and less invasive alternative to these traditional methods. The study involves applying tranexamic acid powder inside the nose to treat active spontaneous nosebleeds. This treatment is being studied as an alternative to cauterization or nasal packing. Participants will receive this sprayed medication during their visit to the emergency department as part of the trial. Participants will be monitored during their emergency department stay to assess how quickly the nosebleed stops, how much pain the treatment causes, and the total time spent in the emergency department. Researchers will also track if participants return for further treatment within 24 hours and up to 5 days after the initial treatment. The main outcome measure is the cessation of nosebleeds on the first day of treatment.
CONDITIONS
Brief Title
Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give informed consent
- Willing to comply with all study procedures and available for the study duration
- Adults 18 years or older
- Male or female
- Presenting to the emergency department with active, spontaneous nosebleed (epistaxis), with anterior or posterior bleeding identified
You will not qualify if you...
- Sinonasal surgery within the last month
- Required medical treatment for nosebleed in the last 30 days
- Septum perforation
- Known bleeding disorders such as thrombocytopenia, hemophilia, hereditary hemorrhagic telangiectasia, or von Willebrand disease
- History of blood clotting problems including stroke or transient ischemic attack
- Known central nervous system diseases including seizures or brain lesions
- Significant skull base trauma or cerebrospinal fluid leak
- Acquired color vision disturbances
- Known blood in urine or kidney-related bleeding
- Pregnant or breastfeeding women
- Allergy or sensitivity to the study medication
- Signs of other emergency conditions like heart attack, stroke, major trauma, shock, or unstable blood flow
- Cognitive limitations or substance abuse affecting reliability
- Other conditions posing risk, unreliability, or interference with assessments
- Currently participating in another interventional clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day 1
Participants receive tranexamic acid powder applied intranasally to treat active nosebleeds in the emergency department.
1 treatment visit (in-person)
Trial Site Locations
Total: 1 location
1
Peterborough Regional Health Centre
Peterborough, Ontario, Canada, K9J 7C6
Actively Recruiting
Research Team
A
Anne Conlin, HBA&Sc, MD, FRCSC
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here